TITLE

1 year of alendronate after 1 year of parathyroid hormone (1-84) treatment increased bone mineral density in osteoporosis

PUB. DATE
January 2006
SOURCE
ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p10
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article focuses on a study conducted to examine the efficacies of alendronate and parathyroid hormone in increasing bone mineral density (BMD) in osteoporosis. Randomized controlled trial was conducted on 238 postmenopausal women 55 to 85 years of age who had osteoporosis. At 24 months, BMD at the lumber spine increased in all 4 groups. BMD at the femoral neck and total hip increased in all groups. Volumetric BMD in trabecular bone at the spine and the hip increased in all 4 groups. Small decreases in volumetric BMD in cortical bone at the hip occurred in all 4 groups. Groups did not differ for clinical fracture and adverse events.
ACCESSION #
19515991

 

Related Articles

  • 1 year of alendronate after 1 year of parathyroid hormone (1-84) treatment increased bone mineral density in osteoporosis: COMMENTARY. Jamal, Sophie A. // ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p10 

    This article comments on a study conducted to examine the efficacies of alendronate and parathyroid hormone (PTH) in increasing bone mineral density (BMD) in osteoporosis. In the study, researchers reported that the increases in BMD observed after 1 year of PTH were lost if therapy was stopped...

  • Skeletal benefits of the anabolic agent teriparatide in patients with glucocorticoid-induced osteoporosis. Constantinescu, Maria Christina // Maedica - a Journal of Clinical Medicine;2008, Vol. 3 Issue 1, p72 

    The article focuses on the study concerning the skeletal benefits of the anabolic agent teriparatide in patients with glucocorticoid-induced osteoporosis. It evaluates the result of a randomized clinical trial in 428 patients with established glucocorticoid-induced osteoporosis who had received...

  • Pharmacist-run teriparatide clinic. Stroup, Jeffrey; Kane, Michael P.; Busch, Robert S. // American Journal of Health-System Pharmacy;11/1/2003, Vol. 60 Issue 21, p2247 

    Decreased bone mineral density results from imbalance of bone remodeling between osteoclasts, associated with bone resorption and osteoblasts. Teriparatide, also known as recombinant parathyroid hormone, stimulates osteoblasts, thereby, representing the first effective anabolic treatment of...

  • Long- Term Results of Taking Fosamax.  // HealthFacts;Apr2004, Vol. 29 Issue 4, p3 

    Discusses the effect of the long-term use of bisphosphonate drug Fosamax on women's health. Concern raised about the safety of the drug; Information on a clinical trial conducted by a research team led by physician Henry G. Bone on women with osteoporosis; Impact of the discontinuation of...

  • Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial. Tomaschitz, Andreas; Fahrleitner-Pammer, Astrid; Pieske, Burkert; Verheyen, Nicolas; Amrein, Karin; Ritz, Ebehard; Kienreich, Katharina; Horina, Jörg H.; Schmidt, Albrecht; Kraigher-Krainer, Elisabeth; Colantonio, Caterina; Meinitzer, Andreas; Pilz, Stefan // BMC Endocrine Disorders;2012, Vol. 12 Issue 1, p19 

    Background: Increasing evidence suggests the bidirectional interplay between parathyroid hormone and aldosterone as an important mechanism behind the increased risk of cardiovascular damage and bone disease observed in primary hyperparathyroidism. Our primary object is to assess the efficacy of...

  • Skeletal Effects of Vitamin D Supplementation in Postmenopausal Black Women. Nieves, J.; Cosman, F.; Grubert, E.; Ambrose, B.; Ralston, S.; Lindsay, R. // Calcified Tissue International;Nov2012, Vol. 91 Issue 5, p316 

    Black women have lower serum 25-hydroxyvitamin D (25[OH]D) levels and higher parathyroid hormone (PTH) levels than white peers but lower bone turnover, suggesting skeletal resistance to PTH. Our objective was to determine if vitamin D supplementation (1,000 IU/day) would prevent bone loss and...

  • Which Inhaler Combination is Best for COPD Treatment? Elliott, William T. // OB/GYN Clinical Alert;Apr2007, Vol. 23 Issue 12, p1 

    The article offers news briefs on issues related to medical care. Two clinical studies were conducted in England to examine the effect of inhaler combinations on outcomes in patients with chronic obstructive pulmonary disease (COPD). The U.S. Food and Drug Administration (FDA) has approved...

  • Alternate Treatment for Osteoporosis.  // Clinical Oncology Alert;Apr2007, Vol. 23 Issue 4, p2 

    The article discusses research being done on a recombinant human parathyroid hormone, a bone forming agent which can be an alternative treatment for osteoporosis. It references a study published in the 2006 issue of "Annals of Internal Medicine." The study concludes that parathyroid hormone...

  • Alternate Treatment for Osteoporosis.  // Infectious Disease Alert;Apr2007, Vol. 26 Issue 7, p2 

    This article discusses findings of a study which focused on recombinant human parathyroid hormone (PTH) as an alternative treatment for osteoporosis. Antiresorptive agents, like bisphosphonates, alendronate and risedronate, are the standard therapy for osteoporosis. PTH is a bone-forming agent,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics